Document is current
Any future updates will be listed below
-
Authors
Hussong, Justine
Leibrock, Berenike
Huelle, Tabea
Mattheus, Hannah
Landfeldt, Erik
Thiele, Simone
Walter, Maggie C.
Zemlin, Michael
Moehler, Eva
Dillmann, Ulrich
Flotats‑Bastardas, Marina
-
Funding
Funding for this research was provided by:
Universität des Saarlandes
- License Information
-
More Information
Article History
Received: 11 November 2025
Accepted: 13 August 2026
First Online: 26 August 2026
Declarations
Ethics approval and consent to participate: The study was approved by the local Ethics Committee of the Saarland Medical Association (February 4, 2020, protocol no. 09/20).
Consent for publication: Not applicable.
Competing interests: Dr Marina Flotats-Bastardas has received consultant fees from Roche and Biogen. Dr Landfeldt is an employee of IQVIA, a contract research organization. Dr Maggie C. Walter has served on advisory boards for Avexis, Biogen, Novartis, Pfizer, Roche, Santhera, Sarepta, Pharnext, PTC Therapeutics, Ultragenyx, Wave Sciences, received funding for Travel or Speaker Honoraria from Avexis, Biogen, PTC Therapeutics, Ultragenyx, Santhera, Sarepta, and worked as an ad-hoc consultant for AskBio, Audentes Therapeutics, Avexis, Biogen Pharma GmbH, Fulcrum Therapeutics, GLG Consult, Guidepoint Global, Gruenenthal Pharma, Novartis, Pharnext, PTC Therapeutics, Roche. Simone Thiele has received financial support for advisory services from PTC Therapeutics. The other authors declare that there is no conflict of interest.
